GEN Exclusives

More »

GEN News Highlights

More »
Sep 28, 2009

AstraZeneca to Help UCB Launch RA/Crohn’s Drug in Brazil

  • AstraZeneca has taken on Brazilian rights to UCB’s Cimzia®, approved in the U.S. for rheumatoid arthritis (RA) and Crohn’s disease. AstraZeneca may also distribute line extensions related to Cimzia in Brazil, while UCB retains the right to co-promote Cimzia and line extensions in the country.

    UCB is developing Cimzia in other autoimmune disease like lupus as well as fracture healing and post-menopausal osteoporosis. The drug is at the Phase II stage for all indications.

    AstraZeneca is responsible for registration and upon approval will be the exclusive distributor of Cimzia, an PEGylated anti-TNF alpha compound in Brazil. Initial registration activities will focus on RA and Crohn’s.

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Mindclones and Immortality

Is the idea of making a software copy of a human mind something in the realm of reality or science fiction?